Table 2.
Cardiometabolic risk parameters (median, IQR)
| Variable | Men (n = 94) | Women (n = 114) | p |
|---|---|---|---|
| Glucose parameters | |||
| Fasting glucose (mg/dL) | 85, 80–90 | 86, 81–92 | 0.4 |
| OGTT 2-h glucose (mg/dL) | 114, 95–133 | 119, 98–134 | 0.6 |
| Fasting insulin (uU/mL) | 14, 9–18 | 8, 5–10 | < 0.0001†*# |
| HOMA-IR | 2.6, 1.7–3.7 | 1.5, 1.0–2.2 | < 0.0001†*# |
| Lipid parameters | |||
| Total cholesterol (mg/dL) | 172, 151–194 | 177, 156–202 | 0.2 |
| HDL cholesterol (mg/dL) | 38, 33–43 | 51, 43–59 | < 0.0001†*# |
| LDL cholesterol (mg/dL) | 107, 93–125 | 106, 87–128 | 0.7 |
| Triglyceride level (mg/dL) | 111, 82–160 | 89, 69–127 | 0.001†*# |
| Apolipoprotein B (ApoB) (mg/dL) | 95, 84–110 | 85, 69–106 | 0.01*# |
| ApoB/LDL | 0.88, 0.83–0.98 | 0.79, 0.70–0.87 | < 0.0001†*# |
| Inflammatory parameters | |||
| hsCRP (ng/L) | 2.4, 1.4–6.0 | 2.9, 1.3–5.5 | 0.8 |
| Fibrinogen (mg/dL) | 395, 344–452 | 475, 419–523 | < 0.0001†*# |
| Metabolic syndrome (n, %) | 34 (37%) | 19 (17%) | 0.002† |
Abbreviations: HOMA-IR homeostatic model assessment of insulin resistance, OGTT oral glucose tolerance test, HDL high-density lipoprotein, LDL low-density lipoprotein, hsCRP high-sensitivity C-reactive protein
†Significant after controlling for multiple comparisons
*Significant after controlling for age
#Significant after controlling for BMI